Small Cell Lung Cancer Clinical Trials
A listing of Small Cell Lung Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 14 clinical trials
Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
Surgery is the best treatment for patients with Stage I or II lung cancer; however, nearly 60% of patients have recurrence. Additional immunotherapeutic agents given before surgery may be greatly reduce recurrence. This is a Standard Phase I, 3+3 dose escalation trial designed to evaluate the safety and toxicity of …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation).
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 15518 / ANAM-17-21: A Phase 3 Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
The main purpose of this study is to learn more about how well the experimental drug, anamorelin hydrochloride (HCl), works to prevent weight loss and anorexia in patients with advanced Non-Small Cell Lung Cancer.
- 0 views
- 19 Feb, 2024
- 1 location
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPVIDO), will limit lung cancer from growing back in patients with early stage non-small cell lung cancer. Nivolumab is a drug that may turn on the body's immune system to attack any cancer …
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 1 Study of the Highly-selective RET
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe. the purpose of this trial is to determine the maximum tolerated …
- 0 views
- 19 Feb, 2024
- 1 location
Substudy: Understanding COVID-19 vaccine responses in the setting of immunotherapy
Anti-PD-1 antibody infusion is now increasingly being tested for other cancers as well, with relatively recent FDA-approval for use in metastatic non-small cell lung cancer, renal cell carcinoma, and metastatic or recurrent head and neck squamous cell carcinoma. This study is designed to better understand antibody responses in the setting …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 06518: A Phase 2 Precision Oncology Study of Biomarker-Directed Pembrolizumab-Based Combination Therapy for Advanced Non-Small Cell Lung Cancer
To evaluate the clinical activity (as assessed by objective response rate [ORR]) pembrolizumab (MK-3475) in combination with MK-4280 or lenvatinib in study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic treatment for their advanced disease.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 16517: A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
- 0 views
- 19 Feb, 2024
- 1 location
- 1
- 2